Advertisement

Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir

  • Atea Pharmaceuticals Inc (NASDAQ: AVIRannounced additional details on its clinical development plans for bemnifosbuvir for COVID-19.

  • Following meetings with the FDA and the European Medicines Agency Emergency Task Force, Atea plans to initiate a global Phase 3 trial of bemnifosbuvir for COVID-19 in the fourth quarter of 2022.

  • The trial will evaluate bemnifosbuvir as both monotherapy and combination antiviral therapy in outpatients (non-hospitalized) with COVID-19 who are at the highest risk of disease progression, regardless of vaccination status.

  • The study is designed to enroll at least 1,500 high-risk non-hospitalized patients with mild or moderate COVID-19.

  • In May, Atea reported a topline analysis of data from the MORNINGSKY trial in which the primary endpoint, time to symptom alleviation, was not achieved.

  • However, a 71% reduction in hospitalization (2.9% versus 10%) was observed in the bemnifosbuvir arm (n=137) versus placebo. In a subgroup analysis, patients > 40 years old had an 82% reduction in hospitalization.

  • New data showed that bemnifosbuvir retained antiviral activity against omicron subvariant lab studies.

  • Price Action: AVIR shares are down 2.51% at $7.78 on the last check Tuesday.

See more from Benzinga

ADVERTISEMENT

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.